Inverse in silico screening for identification of kinase inhibitor targets.

[1]  Thomas Lengauer,et al.  Improved cyclodextrin-based receptors for camptothecin by inverse virtual screening. , 2007, Chemistry.

[2]  Joannis Apostolakis,et al.  GlamDock: Development and Validation of a New Docking Tool on Several Thousand Protein-Ligand Complexes , 2007, J. Chem. Inf. Model..

[3]  M. Zvelebil,et al.  Exploring the specificity of the PI3K family inhibitor LY294002. , 2007, The Biochemical journal.

[4]  B. Schaffhausen,et al.  Essential role of PDK1 in regulating endothelial cell migration , 2007, The Journal of cell biology.

[5]  N. Sagata,et al.  Mechanism for inactivation of the mitotic inhibitory kinase Wee1 at M phase , 2007, Proceedings of the National Academy of Sciences.

[6]  T. Kapoor,et al.  Probing cell-division phenotype space and Polo-like kinase function using small molecules , 2006, Nature chemical biology.

[7]  L. Meijer,et al.  7-Bromoindirubin-3′-oxime induces caspase-independent cell death , 2006, Oncogene.

[8]  G. Kroemer,et al.  Current development of mTOR inhibitors as anticancer agents , 2006, Nature Reviews Drug Discovery.

[9]  M. Neeman,et al.  Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. , 2006, Cancer cell.

[10]  R. Memmott,et al.  Handicapping the Race to Develop Inhibitors of the Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway , 2006, Clinical Cancer Research.

[11]  Didier Rognan,et al.  sc-PDB: an Annotated Database of Druggable Binding Sites from the Protein Data Bank , 2006, J. Chem. Inf. Model..

[12]  J. Lin,et al.  Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer , 2005, British Journal of Cancer.

[13]  N. Hay,et al.  Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo , 2005, Nature Medicine.

[14]  J. Bradbury.  From Chinese medicine to anticancer drugs. , 2005, Drug discovery today.

[15]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[16]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[17]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[18]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[19]  Gerhard Eisenbrand,et al.  Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine , 2004, Journal of Cancer Research and Clinical Oncology.

[20]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[21]  M. Crouch,et al.  Role of the p70S6K pathway in regulating the actin cytoskeleton and cell migration , 2004 .

[22]  D. Alessi,et al.  The serine kinase phosphoinositide-dependent kinase 1 (PDK1) regulates T cell development , 2004, Nature Immunology.

[23]  D. V. van Aalten,et al.  PDK1, the master regulator of AGC kinase signal transduction. , 2004, Seminars in cell & developmental biology.

[24]  N. Paul,et al.  Recovering the true targets of specific ligands by virtual screening of the protein data bank , 2004, Proteins.

[25]  P. Greengard,et al.  GSK-3-selective inhibitors derived from Tyrian purple indirubins. , 2003, Chemistry & biology.

[26]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[27]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[28]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[29]  M. Andjelkovic,et al.  Phosphorylation and activation of p70s6k by PDK1. , 1998, Science.

[30]  Amedeo Caflisch,et al.  Docking small ligands in flexible binding sites , 1998, J. Comput. Chem..

[31]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[32]  R. Glazer,et al.  3-Phosphoinositide-dependent Protein Kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases , 2006, BMC Cancer.